+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort



Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort



Gastroenterology 146(3): 700-708.E2



Individuals who began taking low-dose aspirin before they were diagnosed with colorectal cancer were reported to have longer survival times than patients who did not take this drug. We investigated survival times of patients who begin taking low-dose aspirin after a diagnosis of colorectal cancer in a large population-based cohort study. We performed a nested case-control analysis using a cohort of 4794 patients diagnosed with colorectal cancer from 1998 through 2007, identified from the UK Clinical Practice Research Datalink and confirmed by cancer registries. There were 1559 colorectal cancer-specific deaths, recorded by the Office of National Statistics; these were each matched with up to 5 risk-set controls. Conditional logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI), based on practitioner-recorded aspirin usage. Overall, low-dose aspirin use after a diagnosis of colorectal cancer was not associated with colorectal cancer-specific mortality (adjusted OR = 1.06; 95% CI: 0.92-1.24) or all-cause mortality (adjusted OR = 1.06; 95% CI: 0.94-1.19). A dose-response association was not apparent; for example, low-dose aspirin use for more than 1 year after diagnosis was not associated with colorectal cancer-specific mortality (adjusted OR = 0.98; 95% CI: 0.82-1.19). There was also no association between low-dose aspirin usage and colon cancer-specific mortality (adjusted OR = 1.02; 95% CI: 0.83-1.25) or rectal cancer-specific mortality (adjusted OR = 1.10; 95% CI: 0.88-1.38). In a large population-based cohort, low-dose aspirin usage after diagnosis of colorectal cancer did not increase survival time.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054188386

Download citation: RISBibTeXText

PMID: 24239563

DOI: 10.1053/j.gastro.2013.11.005


Related references

Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study. Bmc Cancer 18(1): 228-228, 2018

Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case-control study. International Journal of Cancer 121(6): 1325-1330, 2007

Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk: A Population-Based, Case-Control Study. Annals of Internal Medicine 163(5): 347-355, 2015

Low-dose aspirin and survival from lung cancer: a population-based cohort study. Bmc Cancer 15(): 911-911, 2016

Low-dose Aspirin Use Does Not Increase Survival in 2 Independent Population-based Cohorts of Patients With Esophageal or Gastric Cancer. Gastroenterology, 2017

Digoxin use after diagnosis of colorectal cancer and survival: a population-based cohort study. Cancer Epidemiology, Biomarkers & Prevention 24(11): 1804-1807, 2016

Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. Journal of Clinical Oncology 32(28): 3177-3183, 2014

New use of low-dose aspirin and risk of colorectal cancer by stage at diagnosis: a nested case-control study in UK general practice. Bmc Cancer 17(1): 637-637, 2017

A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. British Journal of Cancer 88(5): 684-688, 19 March, 2003

Incident cancer risk after the start of aspirin use: results from a Dutch population-based cohort study of low dose aspirin users. International Journal of Cancer 135(1): 157-165, 2014

Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink. Breast Cancer Research 16(2): R34-R34, 2015

Impact of aprepitant on emesis control, dose intensity, and recurrence-free survival in a population-based cohort of head and neck cancer patients receiving high-dose cisplatin chemotherapy. Journal of Community and Supportive Oncology 12(11): 394-400, 2015

Statin use and survival in colorectal cancer: Results from a population-based cohort study and an updated systematic review and meta-analysis. Cancer Epidemiology 45(): 71-81, 2016

Low-dose aspirin use and cancer characteristics a population-based cohort study. British Journal of Cancer 109(7): 1921-1925, 2013

Can aspirin reduce the risk of colorectal cancer in people with diabetes? A population-based cohort study. Diabetic Medicine 32(3): 324-331, 2016